bioMérieux S.A. (BMXXY)

OTCMKTS · Delayed Price · Currency is USD
7.95
-0.07 (-0.87%)
At close: Apr 29, 2026
Market Cap10.21B -35.7%
Revenue (ttm)4.78B +2.3%
Net Income466.71M -8.0%
EPS3.92 -8.2%
Shares Outn/a
PE Ratio21.87
Forward PE16.35
Dividend0.06 (0.72%)
Ex-Dividend DateJun 10, 2025
Volume180
Average Volume5,239
Open7.95
Previous Close8.02
Day's Range7.95 - 7.95
52-Week Range7.95 - 14.62
Beta0.54
RSI39.66
Earnings DateJul 28, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of... [Read more]

Sector Healthcare
Founded 1963
Employees 15,226
Stock Exchange OTCMKTS
Ticker Symbol BMXXY

Financial Performance

In 2025, bioMérieux's revenue was 4.07 billion, an increase of 2.26% compared to the previous year's 3.98 billion. Earnings were 397.50 million, a decrease of -8.03%.

Financial numbers in EUR Financial Statements